Open pergolide treatment of tricyclic and
heterocyclic antidepressant-resistant depression

by
Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y,
Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T
Department of Psychiatry,
Hokkaido University School of Medicine,
North 15, West 7, Kita-ku,
060-8638, Sapporo, Japan
J Affect Disord 2000 Dec 1; 61(1-2):127-132


ABSTRACT

Background: Recently, a dopamine hypothesis of depression was put forward, and several studies have demonstrated that direct and indirect dopamine agonists have antidepressant effects. Methods: Using Clinical Global Impressions, we evaluated the efficacy of 4-week treatment of pergolide as an antidepressant adjuvant involving 20 unipolar depressed patients who were refractory to standard treatment with antidepressants. Results: One patients (5%) were very much improved, seven (35%) much improved, four (20%) minimally improved, six (30%) no change or worse, and two (10%) not assessed. There was no significant difference in any clinical factors between the pergolide responder and non-responder group. Limitations: This study was a non-blind open trial, and pergolide was added to tricyclic and heterocyclic antidepressants. Conclusion: Pergolide may be useful as an antidepressant adjuvant, suggesting a potential role for dopamine-2 stimulation in the antidepressant response.
Cocaine
Pergolide
Selegiline
Roxindole
Dopamine
Ropinirole
Amineptine
Pramipexole
Nomifensine
Bromocriptine
Thyroid hormones
Parkinson's disease
Methylphenidate SR
Dopamine and depression


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family